A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
Stopped the study was terminated due to medication supply issue from current manufacturer
Conditions
- Epithelial Ovarian Cancer
Interventions
- DRUG: CAELYX
- DRUG: Topotecan HCl
Sponsor
Xian-Janssen Pharmaceutical Ltd.